

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)**

Applicant(s): ALLEN et al.

Docket No.

R-611

Serial No.

09/815,937

Filing Date

March 22, 2001

Examiner

Celine X. Qian

Group Art Unit

1636

Invention:

TRANSGENIC MICE CONTAINING LYMPHOID-SPECIFIC GPCR GENE DISRUPTIONS

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

I hereby certify that this Amendment in response to Office Action mailed March 11, 2002

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on August 12, 2002

(Date)

Deborah A. Mojarro

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

COPY OF PAPERS  
ORIGINALLY FILED

Note: Each paper must have its own certificate of mailing.

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
Washington, D.C. 20231



#13/B  
RECEIVED  
8/28/02  
AUG 21 2002  
TECH CENTER 1600/29

In re PATENT APPLICATION of

Inventors **Keith D. ALLEN t al.**

Appln. No.: **09/815,937**

Filed: **March 22, 2001**

Title: **TRANSGENIC MICE CONTAINING LYMPHOID-SPECIFIC GPCR GENE DISRUPTIONS**

Group Art Unit: **1636**

Examiner: **QIAN, CELINE X.**

Docket/Order #: **R-611**

Deposit Acct **50-1271**

Customer # **26619**

Date: **August 12, 2002**

COPY OF PAPER  
ORIGINALLY FILED

## AMENDMENT TRANSMITTAL

Sir:

Please file the enclosed amendment in the above-identified application. The signature below is to be treated as the signature to the enclosure in absence of a signature thereto.

### FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity previously claimed	Claims remaining	Highest # paid for	Present Extra	Small Entity	Add'l Fee	F e Cod
2. Total Claims	23	minus 49=	0	x \$9. =	+ 0	203
3. Independent Claims	10	minus 17=	0	x 42. =	+ 0	202
4. If amendment enters multiple dependent claim(s) for the first..... add				+ \$140. =	+ 0	204
5. Original due date: <b>June 11, 2002</b>						
6. P tition is hereby made to extend the due date to cover the date this r sponse is filed, for which the requisite fee is enclosed				1 mo \$55 2mos \$200 3mos \$460 =	200.00	215 216 217
7. Enter any previous extension fee paid and (subtract)-						
8. Total fee for extension of time:				+ 200.00		
9. If Terminal Disclaimer is enclosed, add Rule 20(d) official fee.....				+ \$55. =	+ 0	248
10. If IDS enclosed requires Official Fee, ..... add				+ \$180. =	+ 0	126
or if Rule 97(d) Petition, ..... add				+ \$130. =	+ 0	122
11. After-Final Request Fee per Rules 129(a) and 17(r).....				+ \$370. =	+ 0	246
12. No. of additional inventions for examination per Rule 129(b):.....				ea x \$370. =	+ 0	249
13. Petition fee for					+ 0	
TOTAL FEE: <input checked="" type="checkbox"/> CHARGE AUTHORIZATION <input type="checkbox"/> ENCLOSED =					\$ 200.00	

Charge Statement: The Commissioner is hereby authorized to charge any missing or insufficient fees relative to this application, or credit any overpayment, to our Account/Order Nos. above, for which purpose a duplicate copy of this sheet is enclosed.

DELTAGEN, INC.

740 Bay Road  
Redwood City, CA 94063  
Tel: (650) 569-5100  
Fax: (650) 569-5280

*Mariette A. Lapi*  
MARIETTE A. LAPIZ, Reg. No. 44,202

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail under 37 C.F.R. 1.8 in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Box Amendment on August 12, 2002.

Date

Name: *Deborah A. Mojarro*  
Deborah A. Mojarro



RECEIVED

AUG 21 2002

TECH CENTER 1600/290

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: ALLEN *et al.*

Group Art Unit: 1636

Serial No.: 09/815,937

Examiner: Qian, Celine X.

Filed: March 22, 2001

Attorney Docket No.: R-611

For: TRANSGENIC MICE CONTAINING LYMPHOID-SPECIFIC GPCR GENE  
DISRUPTIONS

**AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 11, 2002 in connection with the above-identified application, Applicants request entry and consideration of the following amendments and remarks. Applicants submit concurrently herewith a Petition for the Extension of Time under 37 CFR 1.136(a) for response to the Office Action for a period of two months from June 11, 2002 up to and including August 11, 2002.

**AMENDMENTS**

**In the claims:**

Please cancel claims 1-10 and 17-24.

Please add new claims 39-58 as follows:

39. (New) A targeting construct comprising:

- (a) a first polynucleotide sequence homologous to a lymphoid-specific GPCR gene;  
(b) a second polynucleotide sequence homologous to the target gene; and  
(c) a selectable marker located between the first polynucleotide sequence and the second polynucleotide sequence,

wherein the targeting construct, when introduced into murine embryonic stem cells, results in a transgenic mouse having a disruption in a lymphoid-specific GPCR gene, wherein the transgenic mouse when homozygous for the disruption in a lymphoid-specific GPCR gene